MAxL -
Munich Accelerator Life Sciences & Medicine

With MAxL we create the perfect framework conditions for successful start-ups. 

MAxL is BioM's unique co-creation start-up incubator for the future of medicine and life sciences located in Martinsried/Munich, the European hotspot for biotech.

On June 25, 2024, we opened our start-up incubator MAxL together with State Secretary Tobias Gotthardt!


Around 120 invited guests from politics, science, industry and the investment sector celebrated the opening - also present: our first two tenants Leopard Biosciences and RNATICS.

You want to be part of MAxL too? Then get in touch with us!

MAxL Opening (YouTube Video)

This slot is intended for displaying content of the external provider (https://www.youtube.com/). Please be aware that this content as well as the processing of your user data when clicking on this link is outside of bio-m.org's responsibility and potentially not subject to the General Data Protection Regulation anymore. Manage details and settings for cookies and third party providers

 

Based on BioM’s strong expertise, MAxL supports selected pre-seed and early-stage start-up teams with an exclusive high-end infrastructure: shared lab space, co-working and community space for pre-seed and early start-up teams from Bavaria and beyond, structured incubation and coaching program, fully equipped lab workspaces, co-working spaces, meeting and event spaces, and numerous networking opportunities.

We offer partnerships with pharma, big biotech, deeptech and other industry players and strategic partners, CROs and investors.

The project is funded with EUR 8.5 million from 2023-2027 by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy and is managed by the cluster management company BioM.

With MAxL, pre-seed projects and start-ups from life sciences and healthtech receive precisely targeted support:

Where?

•       on around 900 m2 in close proximity to BioM - from from mid-May 2024 onwards

What?

  • Innovative therapeutics (all modalities, including ATMPs such as gene therapy, cell therapy, vaccines)
  • Platform technologies for drug discovery, drug development, drug and vaccine production
  • Next-generation diagnostics and diagnostic platforms
  • Health tech business models based on digital health, Big Data, machine learning and AI
  • Biotechnology-based solutions in the area of bioeconomy

How?

Interested? We are happy to get in touch with you!


Dr. Petra Burgstaller
Dr. Petra Burgstaller

Incubation & MAxL Co-Lead, Portfolio Management

Christina Enke-Stolle
Christina Enke-Stolle

Incubation & MAxL Co-Lead, Partnership Management



More about this topic

BIO-Europe 2024 in Stockholm, Sweden: Meet us at the German Pavilion! Save your 15% BioM discount!

BIO-Europe 2024: Meet us at the Ger­man Pavil­ion!This fall, BIO-Europe re­turns for an en­rich­ing face-to-face ex­per­i­ence, and we're…

Record financing in Martinsried: CatalYm secures 150 million US dollars for breakthrough in cancer treatment

CatalYm has closed a USD 150 mil­lion Ser­ies D fin­an­cing round to ad­vance the fur­ther de­vel­op­ment of its Visu­gromab an­ti­body. The…

SciRhom secures EUR 63 million in Series A financing round for antibody therapy against autoimmune diseases

Martin­sried-based start-up SciRhom has raised €63 mil­lion in a Ser­ies A fin­an­cing round to ad­vance its iRhom2-tar­geted an­ti­body…